Cargando…

Initial clinical outcomes of intracoronary infusion of autologous progenitor cells in patients with acute myocardial infarction

BACKGROUND: Myocardial infarction (MI) is an irreversible cardiomyocytes injury which begins after 15–20 minutes of coronary artery occlusion. The extent of infarction is modulated by a number of factors including collateral blood supplies, medications, and ischemic preconditioning. Although angiopl...

Descripción completa

Detalles Bibliográficos
Autores principales: Jazi, Seyed Mohammad Hashemi, Esfahani, Mohammad Hossein Nasr, Fesharaki, Mehrafarin, Moulavi, Fariba, Gharipour, Mojgan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413085/
https://www.ncbi.nlm.nih.gov/pubmed/23205050
_version_ 1782240022660907008
author Jazi, Seyed Mohammad Hashemi
Esfahani, Mohammad Hossein Nasr
Fesharaki, Mehrafarin
Moulavi, Fariba
Gharipour, Mojgan
author_facet Jazi, Seyed Mohammad Hashemi
Esfahani, Mohammad Hossein Nasr
Fesharaki, Mehrafarin
Moulavi, Fariba
Gharipour, Mojgan
author_sort Jazi, Seyed Mohammad Hashemi
collection PubMed
description BACKGROUND: Myocardial infarction (MI) is an irreversible cardiomyocytes injury which begins after 15–20 minutes of coronary artery occlusion. The extent of infarction is modulated by a number of factors including collateral blood supplies, medications, and ischemic preconditioning. Although angioplasty and thrombolytic agents can relieve the cause of the infarction, the time from the occlusion onset to reperfusion determines the degree of irreversible myocardial injury. Experimental studies suggested that stem cells and progenitor cells derived from bone marrow can be used in the repair of cardiac tissue after acute MI. This study was designed to investigate the feasibility, safety and initial clinical outcome of intracoronary infusion of autologous progenitor cells in patients with acute MI. METHODS: Patients with a history of anterior MI and a left ventricular ejection fraction (LVEF) less than 35 % who were candidates for coronary angioplasty were randomly allocated in a 1:1 ratio to either control or bone marrow cell groups (each including 16 patients). Thallium scan and 17-segment echocardiography analysis for regional wall motion abnormality were performed before and 1 and 6 months after intracoronary infusion of bone marrow cells. The same tests were also conducted for the control group at identical time intervals. Quantitative variables were compared by independent t-test and paired t-test. Statistical significance was assumed at a value of P < 0.05. RESULTS: LVEF in the case and control groups increased to 39.37 ± 2.47% and 31.00 ± 1.87%, respectively (P = 0.069 and 0.1, respectively). Wall motion abnormality index (WMAI) decreased insignificantly in both groups. Perfusion defect scores (PDSs) decreased significantly in the case group. CONCLUSION: In this study, autologous mesenchymal stem cell transplantation by intracoronary catheter during angioplasty in patients with a history of severe LV dysfunction caused mild increases in LVEF.
format Online
Article
Text
id pubmed-3413085
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-34130852012-12-01 Initial clinical outcomes of intracoronary infusion of autologous progenitor cells in patients with acute myocardial infarction Jazi, Seyed Mohammad Hashemi Esfahani, Mohammad Hossein Nasr Fesharaki, Mehrafarin Moulavi, Fariba Gharipour, Mojgan ARYA Atheroscler Articles BACKGROUND: Myocardial infarction (MI) is an irreversible cardiomyocytes injury which begins after 15–20 minutes of coronary artery occlusion. The extent of infarction is modulated by a number of factors including collateral blood supplies, medications, and ischemic preconditioning. Although angioplasty and thrombolytic agents can relieve the cause of the infarction, the time from the occlusion onset to reperfusion determines the degree of irreversible myocardial injury. Experimental studies suggested that stem cells and progenitor cells derived from bone marrow can be used in the repair of cardiac tissue after acute MI. This study was designed to investigate the feasibility, safety and initial clinical outcome of intracoronary infusion of autologous progenitor cells in patients with acute MI. METHODS: Patients with a history of anterior MI and a left ventricular ejection fraction (LVEF) less than 35 % who were candidates for coronary angioplasty were randomly allocated in a 1:1 ratio to either control or bone marrow cell groups (each including 16 patients). Thallium scan and 17-segment echocardiography analysis for regional wall motion abnormality were performed before and 1 and 6 months after intracoronary infusion of bone marrow cells. The same tests were also conducted for the control group at identical time intervals. Quantitative variables were compared by independent t-test and paired t-test. Statistical significance was assumed at a value of P < 0.05. RESULTS: LVEF in the case and control groups increased to 39.37 ± 2.47% and 31.00 ± 1.87%, respectively (P = 0.069 and 0.1, respectively). Wall motion abnormality index (WMAI) decreased insignificantly in both groups. Perfusion defect scores (PDSs) decreased significantly in the case group. CONCLUSION: In this study, autologous mesenchymal stem cell transplantation by intracoronary catheter during angioplasty in patients with a history of severe LV dysfunction caused mild increases in LVEF. Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences 2012 /pmc/articles/PMC3413085/ /pubmed/23205050 Text en © 2012 Isfahan Cardiovascular Research Center & Isfahan University of Medical Sciences http://creativecommons.org/licenses/by-nc/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
spellingShingle Articles
Jazi, Seyed Mohammad Hashemi
Esfahani, Mohammad Hossein Nasr
Fesharaki, Mehrafarin
Moulavi, Fariba
Gharipour, Mojgan
Initial clinical outcomes of intracoronary infusion of autologous progenitor cells in patients with acute myocardial infarction
title Initial clinical outcomes of intracoronary infusion of autologous progenitor cells in patients with acute myocardial infarction
title_full Initial clinical outcomes of intracoronary infusion of autologous progenitor cells in patients with acute myocardial infarction
title_fullStr Initial clinical outcomes of intracoronary infusion of autologous progenitor cells in patients with acute myocardial infarction
title_full_unstemmed Initial clinical outcomes of intracoronary infusion of autologous progenitor cells in patients with acute myocardial infarction
title_short Initial clinical outcomes of intracoronary infusion of autologous progenitor cells in patients with acute myocardial infarction
title_sort initial clinical outcomes of intracoronary infusion of autologous progenitor cells in patients with acute myocardial infarction
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413085/
https://www.ncbi.nlm.nih.gov/pubmed/23205050
work_keys_str_mv AT jaziseyedmohammadhashemi initialclinicaloutcomesofintracoronaryinfusionofautologousprogenitorcellsinpatientswithacutemyocardialinfarction
AT esfahanimohammadhosseinnasr initialclinicaloutcomesofintracoronaryinfusionofautologousprogenitorcellsinpatientswithacutemyocardialinfarction
AT fesharakimehrafarin initialclinicaloutcomesofintracoronaryinfusionofautologousprogenitorcellsinpatientswithacutemyocardialinfarction
AT moulavifariba initialclinicaloutcomesofintracoronaryinfusionofautologousprogenitorcellsinpatientswithacutemyocardialinfarction
AT gharipourmojgan initialclinicaloutcomesofintracoronaryinfusionofautologousprogenitorcellsinpatientswithacutemyocardialinfarction